-
Trump says Iran wants deal, US 'armada' larger than in Venezuela raid
-
US Justice Dept releases new batch of documents, images, videos from Epstein files
-
Four memorable showdowns between Alcaraz and Djokovic
-
Russian figure skating prodigy Valieva set for comeback -- but not at Olympics
-
Barcelona midfielder Lopez agrees contract extension
-
Djokovic says 'keep writing me off' after beating Sinner in late-nighter
-
US Justice Dept releasing new batch of Epstein files
-
South Africa and Israel expel envoys in deepening feud
-
French eyewear maker in spotlight after presidential showing
-
Olympic dream 'not over', Vonn says after crash
-
Brazil's Lula discharged after cataract surgery
-
US Senate races to limit shutdown fallout as Trump-backed deal stalls
-
'He probably would've survived': Iran targeting hospitals in crackdown
-
Djokovic stuns Sinner to set up Australian Open final with Alcaraz
-
Mateta omitted from Palace squad to face Forest
-
Gold, silver prices tumble as investors soothed by Trump's Fed pick
-
Trump attorney general orders arrest of ex-CNN anchor covering protests
-
Djokovic 'pushed to the limit' in stunning late-night Sinner upset
-
Tunisia's famed blue-and-white village threatened after record rains
-
Top EU official voices 'shock' at Minneapolis violence
-
Kremlin says agreed to halt strikes on Kyiv until Sunday
-
Carrick calls for calm after flying start to Man Utd reign
-
Djokovic to meet Alcaraz in Melbourne final after five-set marathon
-
Italian officials to testify in trial over deadly migrant shipwreck
-
Iran says defence capabilities 'never' up for negotiation
-
UN appeals for more support for flood-hit Mozambicans
-
Lijnders urges Man City to pile pressure on Arsenal in title race
-
Fulham sign Man City winger Oscar Bobb
-
Strasbourg's Argentine striker Panichelli sets sights on PSG, World Cup
-
Jesus 'made love': Colombian president irks Christians with steamy claim
-
IAEA board meets over Ukraine nuclear safety concerns
-
Eurozone growth beats 2025 forecasts despite Trump woes
-
Israel to partially reopen Gaza's Rafah crossing on Sunday
-
Dutch PM-elect Jetten says not yet time to talk to Putin
-
Social media fuels surge in UK men seeking testosterone jabs
-
Forest face Fenerbahce, Celtic draw Stuttgart in Europa League play-offs
-
US speed queen Vonn crashes at Crans-Montana, one week before Olympics
-
Trump nominates former US Fed official as next central bank chief
-
Alcaraz defends controversial timeout after beaten Zverev fumes
-
New Dutch government pledges ongoing Ukraine support
-
Newcastle still coping with fallout from Isak exit, says Howe
-
Chad, France eye economic cooperation as they reset strained ties
-
Real Madrid to play Benfica, PSG face Monaco in Champions League play-offs
-
Everton winger Grealish set to miss rest of season in World Cup blow
-
Trump brands Minneapolis nurse killed by federal agents an 'agitator'
-
Arteta focuses on the positives despite Arsenal stumble
-
Fijian Drua sign France international back Vakatawa
-
Kevin Warsh, a former Fed 'hawk' now in tune with Trump
-
Zverev rails at Alcaraz timeout in 'one of the best battles ever'
-
Turkey leads Iran diplomatic push as Trump softens strike threat
| RBGPF | 1.65% | 83.78 | $ | |
| SCS | 0.12% | 16.14 | $ | |
| RYCEF | -2.69% | 16 | $ | |
| CMSC | 0.02% | 23.7 | $ | |
| BCC | -0.97% | 79.4 | $ | |
| BTI | -0.12% | 60.135 | $ | |
| RELX | -1.69% | 35.565 | $ | |
| NGG | -0.81% | 84.37 | $ | |
| GSK | 1.33% | 51.34 | $ | |
| RIO | -4.86% | 90.725 | $ | |
| JRI | 0.32% | 12.997 | $ | |
| CMSD | -0.12% | 24.03 | $ | |
| BCE | -0.18% | 25.44 | $ | |
| VOD | -0.58% | 14.625 | $ | |
| AZN | 0.75% | 93.285 | $ | |
| BP | -1.1% | 37.625 | $ |
Monsanto: object of Bayer desire despite GMO fears
German pharmaceutical giant Bayer sees in agroindustry giant Monsanto a gem worth at least $62 million for its dominant global position selling seeds sought by farmers of corn, soybeans, cotton and other commodity crops.
But for the Green movement, especially in Europe, Monsanto turns stomachs for unstinting promotion of genetically modified crops and its widely used herbicide Roundup, often feared as a possible carcinogen.
The merger is still under discussion -- Monsanto rejected the price as too low on Tuesday, but said it is willing to keep talking.
But it raises questions across an industry that is pushing the frontiers of biochemistry amid great nervousness, and consolidating into just a handful of very powerful firms.
- What is Monsanto? -
St. Louis, Missouri-based Monsanto was established by pharmacist John Queeny in 1901 to produce saccharine. Queeny named the company after his wife Olga Monsanto Queeny.
By the 1940s, the company was producing farm-oriented chemicals, particularly the widely used herbicide 2,4-D, and slowly became a US household name.
Combined with another dangerous chemical, 2,4-D was used to make the notorious Vietnam War-era defoliant Agent Orange.
In 1976, it launched probably its most famous product, Roundup, the world's most widely used herbicide. Its active chemical is glyphosate.
The company began in the 1970s looking at the crops that the herbicides were protected, building cell and molecular biology units. In 1982, its scientists were the first to genetically modify a plant cell.
Monsanto then started buying other seed companies and withing five years began field trials of genetically modified seeds.
It eventually developed soybean, corn, cotton, canola and other crops that were genetically engineered to be tolerant of Roundup.
In 1994, Monsanto also became the first to begin selling the biotechnology-based hormone for dairy cows, rBST and rBGH, which was used across the United States to boost milk production. The two have been banned by many other major dairy producers.
- Why is Monsanto so valuable to Bayer? -
Monsanto is by far the world's leading producer of genetically modified crop seeds, and in many of its seed lines it has a dominant market position.
According to Farm Journal, it had 35.5 percent of the market for corn in the United States in 2014. It had a 28 percent share for soybeans, behind DuPont.
The company owns around 1,700 patents. In 1991, it lost its patent on glyphosate herbicide, but retains a huge market share in part by having marketed its "Roundup-Ready" genetically modified seeds.
Monsanto also owns one of the leading data analytics firms for farmers, Climate Corp.
- What makes Monsanto so controversial? -
Many people and countries, especially in Europe, have not accepted the use of genetically modified organisms -- which they label "frankenfoods."
They say GMO seeds are dangerous to introduce to the farm and food system generally, and foods produced from GMO crops could turn out unsafe to eat.
In addition, Monsanto's strong market position, critics say, can leave farmers dependent on it because they cannot reproduce Monsanto crops with their own seeds due to the company's patents.
In addition, critics say the herbicides the company sells are dangerous to human health, and some have been banned in certain countries.
A merger with Bayer thus could give the combined company even more power in the market, with farmers already facing consolidation among suppliers.
In December, DuPont and Dow Chemical announce plans to merge, and in China National Chemical Corp. or ChemChina, made a $43 billion offer for Syngenta.
N.Walker--AT